NO961706L - Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme - Google Patents

Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme

Info

Publication number
NO961706L
NO961706L NO961706A NO961706A NO961706L NO 961706 L NO961706 L NO 961706L NO 961706 A NO961706 A NO 961706A NO 961706 A NO961706 A NO 961706A NO 961706 L NO961706 L NO 961706L
Authority
NO
Norway
Prior art keywords
disclosed
colorectal cancer
pct
cancer cells
receptor binding
Prior art date
Application number
NO961706A
Other languages
English (en)
Other versions
NO961706D0 (no
NO318980B1 (no
Inventor
Scott A Waldman
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/141,892 external-priority patent/US5518888A/en
Priority claimed from US08/305,056 external-priority patent/US5601990A/en
Application filed by Univ Jefferson filed Critical Univ Jefferson
Publication of NO961706D0 publication Critical patent/NO961706D0/no
Publication of NO961706L publication Critical patent/NO961706L/no
Publication of NO318980B1 publication Critical patent/NO318980B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/08Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5753Immunoassay; Biospecific binding assay; Materials therefor for cancer of the stomach or small intestine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/24Assays involving biological materials from specific organisms or of a specific nature from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • G01N2333/245Escherichia (G)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Optics & Photonics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO19961706A 1993-10-26 1996-04-26 Konjugerte forbindelser, anvendelse av konjugerte forbindelser og farmasoytiske sammensetninger omfattende slike, samt in vitro fremgangsmater og sett for behandling og diagnostikk av kolorektal cancer. NO318980B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/141,892 US5518888A (en) 1993-10-26 1993-10-26 ST receptor binding compounds and methods of using the same
US08/305,056 US5601990A (en) 1994-09-13 1994-09-13 Methods of diagnosing colorectal tumors and metastasis thereof
PCT/US1994/012232 WO1995011694A1 (en) 1993-10-26 1994-10-26 Compositions that specifically bind to colorectal cancer cells and methods of using the same

Publications (3)

Publication Number Publication Date
NO961706D0 NO961706D0 (no) 1996-04-26
NO961706L true NO961706L (no) 1996-06-20
NO318980B1 NO318980B1 (no) 2005-05-30

Family

ID=26839545

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19961706A NO318980B1 (no) 1993-10-26 1996-04-26 Konjugerte forbindelser, anvendelse av konjugerte forbindelser og farmasoytiske sammensetninger omfattende slike, samt in vitro fremgangsmater og sett for behandling og diagnostikk av kolorektal cancer.

Country Status (10)

Country Link
US (1) US6060037A (no)
EP (1) EP0734264B1 (no)
JP (2) JP4194113B2 (no)
AT (1) ATE259648T1 (no)
AU (1) AU681920B2 (no)
CA (1) CA2174928C (no)
DE (1) DE69433564T2 (no)
ES (1) ES2216004T3 (no)
NO (1) NO318980B1 (no)
WO (1) WO1995011694A1 (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658782A (en) * 1993-10-20 1997-08-19 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University A Non-Profit Organization Amino acid transporters and uses
US5912171A (en) * 1993-10-20 1999-06-15 Oregon Health Science University Amino acid transporters and uses
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US7097839B1 (en) * 1993-10-26 2006-08-29 Thomas Jefferson University ST receptor binding compounds and methods of using the same
US6602659B1 (en) 1996-05-03 2003-08-05 Thomas Jefferson University Methods of and kits and compositions for diagnosing colorectal tumors and metastasis thereof
DE69723580T2 (de) * 1996-05-03 2004-06-03 Thomas Jefferson University Impfstoff gegen metastasierenden kolorektalkrebs.
US6106804A (en) * 1997-06-13 2000-08-22 The University Of New Mexico Arsenic-72 labeled compounds for tissue specific medical imaging
US6120995A (en) * 1997-08-07 2000-09-19 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
US7135333B1 (en) 1997-08-07 2006-11-14 Thomas Jefferson University Compositions that specifically bind to colorectal cancer cells and methods of using the same
WO1999021587A1 (en) * 1997-10-15 1999-05-06 Nycomed Imaging As Complexing agents and targeting immunoreagents
WO1999021013A1 (en) * 1997-10-21 1999-04-29 The Regents Of The University Of California Target sequences for synthetic molecules and methods of using same
WO1999039748A1 (en) * 1998-02-06 1999-08-12 Nycomed Imaging As Targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
US6962779B1 (en) 1998-10-02 2005-11-08 Diadexus, Inc. Method of diagnosing, monitoring, staging, imaging and treating gastrointestinal cancers
FR2805994A1 (fr) * 2000-03-10 2001-09-14 Agronomique Inst Nat Rech Methode de detection de la guanylyl cyclase-c et son utilisation pour le diagnostic des tumeurs colorectales metastatiques
ES2548381T3 (es) 2000-03-27 2015-10-16 Thomas Jefferson University Composiciones para el tratamiento e imágenes de células de cáncer estomacales y de esófago
US20050287638A1 (en) * 2000-04-25 2005-12-29 Weigel Paul H Hyaluronan receptor for endocytosis, variants thereof, and methods of making and using same
US6979555B2 (en) * 2000-04-25 2005-12-27 Board Of Regents Of The University Of Oklahoma Hyaluronan receptor for endocytosis
US7829276B2 (en) 2000-09-18 2010-11-09 Thomas Jefferson University Methods of using CRCA-1 as a stomach and esophageal cancer marker
GB0105224D0 (en) 2001-03-02 2001-04-18 Nycomed Amersham Plc Improved peptide-chelate conjugates
ES2622468T3 (es) * 2001-03-29 2017-07-06 Synergy Pharmaceuticals, Inc. Agonistas del receptor de guanilato ciclasa para el tratamiento de inflamación tisular y carcinogénesis
WO2002086093A2 (en) * 2001-04-25 2002-10-31 Weigel Paul H Methods of using a hyaluronan receptor
US20030232013A1 (en) * 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
SI1594517T1 (sl) * 2003-01-28 2007-10-31 Microbia Inc Sestavki za zdravljenje gastrointestinalnih motenj
US7772188B2 (en) * 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7371727B2 (en) * 2003-01-28 2008-05-13 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US7304036B2 (en) 2003-01-28 2007-12-04 Microbia, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20060281682A1 (en) * 2003-01-28 2006-12-14 Currie Mark G Methods and compositions for the treatment of gastrointestinal disorders
US8206704B2 (en) 2003-02-10 2012-06-26 Thomas Jefferson University Use of GCC ligands
PT1644021E (pt) 2003-06-13 2013-01-30 Ironwood Pharmaceuticals Inc Métodos e composições para o tratamento de distúrbios gastrointestinais
US7494979B2 (en) * 2003-06-13 2009-02-24 Ironwood Pharmaceuticals, Inc. Method for treating congestive heart failure and other disorders
GB0403856D0 (en) * 2004-02-20 2004-03-24 Algeta As Composition
ES2451496T3 (es) 2004-06-25 2014-03-27 Thomas Jefferson University Ligandos de guanilato ciclasa C
EP1940441A4 (en) * 2005-08-19 2010-01-27 Ironwood Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING GASTROINTESTINAL DISORDERS
CA2652677A1 (en) * 2006-02-24 2007-09-07 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
US20100120694A1 (en) * 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
EP2296685B1 (en) 2008-06-04 2015-09-02 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼcアゴニストの製剤およびその使用方法
AU2010217160C1 (en) 2009-02-25 2015-07-02 Diagnocure Inc. Method for detecting metastasis of GI cancer
US8785600B2 (en) * 2009-10-23 2014-07-22 Millennium Pharmaceuticals, Inc. Anti-GCC antibody molecules and related compositions and methods
PH12012500916B1 (en) * 2009-11-09 2018-03-23 Ironwood Pharmaceuticals Inc Treatments for gastrointestinal disorders
KR20120103689A (ko) 2009-12-07 2012-09-19 아이언우드 파마슈티컬스, 인코포레이티드 위장 장애의 치료
JP5610125B2 (ja) * 2010-02-22 2014-10-22 国立大学法人 長崎大学 癌転移の検出方法および検出用キット
EP2605786A4 (en) * 2010-06-09 2014-03-12 Combimab Inc THERAPEUTIC PEPTIDES
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2810243C (en) 2010-09-15 2021-04-20 Synergy Pharmaceuticals Inc. Formulations of guanylate cyclase c agonists and methods of use
US9303066B2 (en) 2011-05-11 2016-04-05 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
CA2835624A1 (en) 2011-05-11 2012-11-15 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170804A1 (en) 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
WO2012170766A1 (en) 2011-06-08 2012-12-13 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
ES2402014B1 (es) 2011-09-07 2014-02-27 Consejo Superior De Investigaciones Científicas (Csic) Peptido secretado por lactobacillus plantarum con función inmunomoduladora
CA2871614C (en) 2012-04-27 2021-08-31 Millennium Pharmaceuticals, Inc. Anti-gcc antibody molecules and use of same to test for susceptibility to gcc-targeted therapy
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
JP2014158468A (ja) * 2014-03-05 2014-09-04 Clinical Genomics Pty Ltd 検出方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584268A (en) * 1981-10-13 1986-04-22 Ceriani Roberto Luis Method and compositions for carcinoma diagnosis
US4965188A (en) * 1986-08-22 1990-10-23 Cetus Corporation Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US5160723A (en) * 1985-04-19 1992-11-03 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
US5075216A (en) * 1988-09-23 1991-12-24 Cetus Corporation Methods for dna sequencing with thermus aquaticus dna polymerase
US5237051A (en) * 1990-12-06 1993-08-17 Vanderbilt University Purified enterotoxin receptor protein
US5237015A (en) * 1991-11-04 1993-08-17 Polysar Rubber Corporation Core-shell polymer for use in tire treads
US5879656A (en) * 1993-10-26 1999-03-09 Thomas Jefferson University Methods of treating metastatic colorectal cancer with ST receptor binding compounds
US5601990A (en) * 1994-09-13 1997-02-11 Thomas Jefferson University Methods of diagnosing colorectal tumors and metastasis thereof
US5518888A (en) * 1993-10-26 1996-05-21 Thomas Jefferson University ST receptor binding compounds and methods of using the same

Also Published As

Publication number Publication date
EP0734264A1 (en) 1996-10-02
NO961706D0 (no) 1996-04-26
DE69433564D1 (de) 2004-03-25
AU681920B2 (en) 1997-09-11
EP0734264B1 (en) 2004-02-18
US6060037A (en) 2000-05-09
ES2216004T3 (es) 2004-10-16
CA2174928C (en) 2011-08-16
ATE259648T1 (de) 2004-03-15
EP0734264A4 (en) 1999-04-21
JP4684940B2 (ja) 2011-05-18
WO1995011694A1 (en) 1995-05-04
JP4194113B2 (ja) 2008-12-10
NO318980B1 (no) 2005-05-30
CA2174928A1 (en) 1995-05-04
JPH09506340A (ja) 1997-06-24
JP2006246895A (ja) 2006-09-21
AU8124994A (en) 1995-05-22
DE69433564T2 (de) 2004-12-23

Similar Documents

Publication Publication Date Title
NO961706L (no) Sammensetning som særlig binder seg til kolorektale kreftceller, samt fremgangsmåte for anvendelse av samme
AU1378499A (en) Methods for treating prostate tumors using radioactive compositions
MX9700553A (es) Anticuerpos que activan un receptor de eritropoyetina.
ATE370967T1 (de) Polyspezifische bindemoleküle und deren verwendung
MY139226A (en) Compositions and methods for wt1 specific immunotherapy
TR200003087T2 (tr) Yeni CD19 X CD3 Spesifik polipeptidler ve kullanımları
EP0751962A4 (en) METHODS AND COMPOSITIONS FOR INHIBITING THE ACTIVATION OF CD14-INDUCED CELLS
NO20003552L (no) Progesteron-agonistforbindelser, farmasøytiske sammensetninger inneholdende disse og anvendelsen av forbindelsen, samt en fremgangsmÕte for bestemmelse av tilstedeværelse av steroidreseptorer, ligand-steroidreseptorkomplekser og en fremgangsmÕte
MY141605A (en) Method of treating certain cancers using an estrogen agonist/antagonist
MX9709442A (es) Metodo y composiciones para la inhibicion de interacciones entre proteina adaptadora y tirosinquinasa.
MX9804358A (es) Apoptosis inducida por el anticuerpo monoclonal anti-her2.
ES2293973T3 (es) Anticuerpos anti-ccr2 humanizados y metodos de uso de los mismos.
ATE193542T1 (de) Verfahren und verbindungen zum screening von presynaptischen calcium kanal inhibitoren
AU1929199A (en) Methods for the recovery and measurement of troponin complexes
AU9779498A (en) Sphingosine-1-phosphate lyase polypeptides, polynucleotides and modulating agents and methods of use therefor
FI973118A0 (fi) Lymfotoksiini-alfa/beta-komplekseja ja antilymfotoksiini-beta-reseptorivasta-aineita kasvaimenvastaisina aineina
EP0753072A1 (en) Biological markers of benign prostate hyperplasia
NO964015L (no) Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer
NZ501990A (en) Compositions containing antigen-binding fragments that recognise the antigen recognised by a recombinant 4B5 antibody
AU2001233913A1 (en) Bcmp 84, a protein associated to breast cancer
WO2001032210A3 (en) Compositions for treating atheroma and neoplastic tissue
EP0660932A4 (en) METHOD FOR PRODUCING TEST ELEMENTS.
Moul et al. Immunohistologic detection of prostate cancer pelvic lymph node micrometastases: correlation to preoperative serum prostate-specific antigen
AU2003242815A1 (en) Method for the characterisation of circulating tumour cells stemming from solid cancers
MX9702789A (es) Novedosas proteinas ligandos del dominio de la muerte del receptor tnf, e inhibidores de la union delos ligandos.